128 related articles for article (PubMed ID: 37725566)
21. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
22. Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.
Jeon Y; Park S; Lee SH; Kim TH; Kim SW; Ahn MJ; Jung HA; Chung JH
Cancer Res Treat; 2024 Mar; ():. PubMed ID: 38453274
[TBL] [Abstract][Full Text] [Related]
23. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
24. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
[TBL] [Abstract][Full Text] [Related]
25. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.
Isberner N; Gesierich A; Balakirouchenane D; Schilling B; Aghai-Trommeschlaeger F; Zimmermann S; Kurlbaum M; Puszkiel A; Blanchet B; Klinker H; Scherf-Clavel O
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230489
[TBL] [Abstract][Full Text] [Related]
27. Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAF
Martín-Soberón MC; Ruiz S; De Velasco G; Yarza R; Carretero A; Castellano D; Sepúlveda-Sánchez JM
J Med Case Rep; 2021 Mar; 15(1):109. PubMed ID: 33653337
[TBL] [Abstract][Full Text] [Related]
28. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
29. A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated
Awada G; Schwarze JK; Tijtgat J; Fasolino G; Everaert H; Neyns B
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33921947
[TBL] [Abstract][Full Text] [Related]
30. The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan.
Chang CF; Yang MH; Lee JH; Shih SR; Lin CH; Chen CP; Wu CE; Lu JY
Am J Cancer Res; 2022; 12(11):5342-5350. PubMed ID: 36504909
[TBL] [Abstract][Full Text] [Related]
31. Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic-pharmacodynamic real-life study.
Goldwirt L; Louveau B; Baroudjian B; Allayous C; Jouenne F; Da Meda L; Vu LT; Sauvageon H; Herms F; Delyon J; Lebbé C; Mourah S
Cancer Chemother Pharmacol; 2021 Sep; 88(3):427-437. PubMed ID: 34057572
[TBL] [Abstract][Full Text] [Related]
32. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836
[TBL] [Abstract][Full Text] [Related]
33. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
[TBL] [Abstract][Full Text] [Related]
34. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.
Dotinga M; Vriens D; van Velden F; Heijmen L; Nagarajah J; Hicks R; Kapiteijn E; de Geus-Oei LF
Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):250-264. PubMed ID: 32744039
[TBL] [Abstract][Full Text] [Related]
35. Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma.
Rousset M; Dutriaux C; Bosco-Lévy P; Prey S; Pham-Ledard A; Dousset L; Gérard E; Bouchet S; Canal-Raffin M; Titier K; Molimard M
Clin Chim Acta; 2017 Sep; 472():26-29. PubMed ID: 28709799
[TBL] [Abstract][Full Text] [Related]
36. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
Schadendorf D; Robert C; Dummer R; Flaherty KT; Tawbi HA; Menzies AM; Banerjee H; Lau M; Long GV
Eur J Cancer; 2021 Aug; 153():234-241. PubMed ID: 34225229
[TBL] [Abstract][Full Text] [Related]
37. Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.
Lin L; Barkman HJ; Smit EF; de Langen AJ; Steeghs N; Beijnen JH; Huitema ADR
Ther Drug Monit; 2024 Feb; 46(1):73-79. PubMed ID: 37348074
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of Radioiodine Uptake by Pulmonary Metastasis of Papillary Thyroid Carcinoma Treated with Dabrafenib and Trametinib.
Malja E; Kandathil A; Peng F
Nucl Med Mol Imaging; 2024 Apr; 58(2):92-94. PubMed ID: 38510823
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.
Kim HY; Duong JK; Gonzalez M; Long GV; Menzies AM; Rizos H; Lim SY; Lee J; Boddy AV
Cancer Chemother Pharmacol; 2019 Apr; 83(4):693-704. PubMed ID: 30661097
[TBL] [Abstract][Full Text] [Related]
40. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
